Fagron Belgium’s Post

Exciting insights from today’s Personalized Medicine / Precision Medicine Conference, hosted by the Danish Pharmaceutical Association (LIF) and the Ministry of Interior and Health. Key takeaways: 💡 LIF urged that Denmark’s upcoming personalized medicine strategy position the country as a leader in advanced therapy medicinal products (ATMPs) by establishing a Center of Excellence, fostering partnerships, building expertise, and leveraging the nation’s vast health data resources. 🚪 Amgros advocated for a unified access point to streamline ATMP deployment. 👨⚕️ Hospital representatives emphasized the importance of viewing personalized medicine holistically—as a data-driven approach to individual treatment. They highlighted the need to modernize legal frameworks and reduce barriers to optimize resource allocation, minimize unnecessary treatments, and promote equality in healthcare. Thanks to the organisers and all the speakers from Lif - Lægemiddelindustriforeningen, Indenrigs- og Sundhedsministeriet, Amgros I/S, Danske Regioner - Danish Regions, Rigshospitalet, University of Copenhagen (Københavns Universitet), Sjællands Universitetshospital, Sjældne Diagnoser, European Medicines Agency

Hear hear! If you are still thinking about #Singapore #PharmacyCongress2024, there is no need to think any further! The annual Pharmaceutical Society of Singapore (PSS) Congress, this year, makes it regional!

📣Call for Abstracts: 2nd MENA Sterilisation Symposium 😃We are pleased to announce that the 2nd MENA Sterilisation Symposium is now accepting abstract submissions. This event aims to gather experts and professionals from the Middle East and North Africa region to discuss the latest advancements and challenges in sterilisation practices. 👉Important Dates: Abstract Submission Deadline: 30 May 2024 Symposium Dates: 21-23 June 2024 Submission Guidelines: Content: Abstracts should be original and relevant to sterilisation practices, including but not limited to: *Innovations in sterilisation technologies *Best practices and standards *Sterilisation in healthcare settings or industry *Regulatory and compliance issues *Case studies and research findings Format: Abstracts should be concise and no longer than 300 words. Please include the following: Title Author(s) name(s) and affiliation(s) Background/Objectives Methods Results Conclusions Submission: Submit your abstract via email to menasterilization@gmail.com with the subject line "Abstract Submission – 2nd MENA Sterilisation Symposium." 🌟Review Process: All submissions will be reviewed by the Symposium Committee. Authors will be notified of acceptance by 10 June 2024. 🙏We look forward to your contributions to this important event.

A Resounding Success in in MEDICA 2024 https://lnkd.in/eENCcCp9

Today was released the OECD report Securing Medical Supply Chains in a Post-Pandemic World, in which I had the privilege to collaborate in my time working with the fantastic Pharmaceutical Team at the OECD Health Division. ⚡Some highlights: -Reliable medical supply chains are a cornerstone of resilient health systems. -Shortages of medicines were already common before COVID-19, and the pandemic exacerbated this problem. -Policy action, complemented by international cooperation and collaboration with the private sector, must be taken to strengthen supply chains now and in anticipation of future health crises. -Collaborating and sharing information among stakeholders, as well as enhancing international cooperation among governments, will be key. Read the full report here 👇

Czechia pushes for EU coordination in medicine stockpiling, offers resilient model for future: In a push to prevent medicine shortages across Europe, Czechia is advocating for a more coordinated approach to medicine stockpiling. The aim is to strengthen supply chains and ensure preparedness.

Asrar Qureshi’s Blog Post #963 is published in Pharma Veterans. Please read it here. https://lnkd.in/dGwW_nW4 #asrarqureshi #pharmaveterans #healthcare #patient #doctor #hospital #lab #pharmacy #blogpost963

🌟 Excited to share our recent overview of reviews on de-implementation strategies of low value healthcare practices! 🌟 As part of the REMOVE-project led by Christina Kien and funded by Gesellschaft für Forschungsförderung Niederösterreich m.b.H., this overview of systematic reviews aimed to investigate the effectiveness of de-implementation initiatives and specifc ERIC strategy clusters. Christina Kien, Julia Daxenbichler, Viktoria Tischer, Julia Bänziger, Rahel Naef, Irma Klerings, Lauren Clack, Julian Fila, Isolde Sommer and me explored effective ways to reduce low-value care (LVC), crucial for enhancing patient outcomes and optimizing healthcare resources. By analyzing 46 systematic reviews spanning drug treatments, laboratory tests, diagnostic imaging, and other healthcare practices, we uncovered compelling findings. Key Highlights: 🔍  De-implementation initiatives were effective in reducing medication usage, and inconsistent signifcant reductions were observed for LVC laboratory tests and imaging. 📉 De-implementation clusters such as change infrastructure and workfow and develop stakeholder interrelationships emerged as the most encouraging avenues. 💡 Moreover, we provided suggestions to enhance future systematic reviews quality, emphasising adherence to guidelines for synthesising complex interventions, prioritising appropriateness of care outcomes, documenting the development process of deimplementation initiatives and ensuring consistent reporting of applied de-implementation strategies. Open Access full text here: https://lnkd.in/d32TrZRi #Deimplementation #lowvaluecare #HealthcareResearch #overviewofreviews

EAPM roundtable at EHA Congress, Madrid, 14 June 2024 Brussels, June 4th, 2024: For the 10th year in succession, EAPM will be present at the prestigious EHA Congress and will, for the fourth time, be hosting a satellite meeting as part of the events. In the same way as our  own recent events, the focus will be on bringing innovation into healthcare systems, but with very specific spotlight on the new European Parliament and European Commission. Sessions will focus on topic on how to enable equal access: what are the policy and health technology assessment implications? There will be a specific focus on different countries and the way that they are tackling the implementation gap.  Sessions will feature panel discussions as well as time for questions and answers and we would very much like you to join us at the event, which runs from 14.00 – 17.00 CET on Friday, June 14th, 2024. Please click HERE (https://lnkd.in/eVvrTjbN) to register and please click HERE to see the agenda (https://lnkd.in/egu8YKGx)  Every stakeholder in personalised medicines knows what the drivers of this innovative new form of healthcare are. For patients and healthcare professionals it means more options, durable clinical benefit, reduced exposure to non-effective drugs and the potential to leverage current scientific and technological advances. For the pharmaceutical industry, we’re talking about the potential to tackle core challenges in discovering and developing more effective medicines, to reduce rates of attrition in drug development, and to reduce the associated escalating costs which are central to a more sustainable future and delivery for healthcare needs. Meanwhile, for healthcare systems and payers, the drivers are improved efficiency through the provision of efficacious and cost-effective care through the avoidance of ineffective and redundant interventions. These are again key to a more sustainable and deliverable future system. The question of whether innovation is really giving us value for money often arises. The debate has focussed to a large extent on the cost of “doing something”. Yet surely we also need to remember to ask ‘what about the cost of not doing something? Diagnostic and therapeutic innovation must be implemented in a structured cost-effective approach that emphasises measurable improvements in outcome for the patient in the personalised healthcare era.   Resources are scarce for all of us working in healthcare, which is exacerbated by an ageing population and the consequent increase in chronic diseases and co-morbidities. Please click HERE (https://lnkd.in/eVvrTjbN) to register and please click HERE to see the agenda (https://lnkd.in/egu8YKGx)  Lars Bullinger, Giovanni Martinelli, Robin Doeswijk, Guillermo Sanz, Ellen [P.B.] de Waal, Ineke van der Beek, Ane, Anđela Škarpa, Sirpa Pietikäinen, Raffaella Colombatti, Sonia Ujupan, Hilary M. Hansen